Advertisement


Axel Hauschild, MD, on Melanoma: Findings From the PIVOTAL Trial of Daromun vs Surgery

2024 ASCO Annual Meeting

Advertisement

Axel Hauschild, MD, of Germany’s University of Kiel and University Hospital Schleswig-Holstein, discusses phase III study results on neoadjuvant intralesional daromun vs immediate surgery for patients with fully resectable, locally advanced melanoma (Abstract LBA9501).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
I'd like to report about a study which was called PIVOTAL. It's a clinical trial on Daromun, a new agent which was not discovered so far in a Phase III trial. The trial design is very simple. It was a one-to-one randomization of 260 patients. In one arm is surgery alone for fully resectable stage III melanoma patients with either lymph node or skin metastases. The other arm was a prior treatment, prior to surgery, with four consecutive injections intratumorally, for the skin and lymph nodes with Daromun. I need to explain Daromun briefly because the agent is new. It's a composition of an L19 antibody directed to fibronectin, which is a crucial molecule for the development of neovascularization, particularly in tumors. And this is linked to interleukin 2, which enhances the number of tumor infiltrating lymphocyte in the tumor, and in addition to another antibody, which is linked to the drug, which is very important for the tumor necrosis, the tumor necrosis factor alpha. It's two component brought to one injection, and this has been done four consecutive times. The result of the study is that the primary endpoint, which is relapse three survival is positive. A positive randomized phase III trial and the hazard ratio is 0.59, corresponding to a more than 40% reduction of the risk for recurrence and the risk of death. Secondary endpoints as distant metastasis-free survival were also positive. In the same ballpark, the hazard ratio here is .60, so 40% reduction in the risk to develop distant metastases. I need to mention that there was a study amendment which allowed us to evaluate the tumor specimens, which have been treated by Daromun, and the rate of pathologically confirmed complete responses is 21%. Further read shots on this is following. Of note, there was almost no systemic toxicity. All of the toxicities were local. It was very well tolerated, it was manageable, and the mean number of administered cycles was three, the median number was four. Almost all patients got the full package of four injections. In general, I need to say and conclude, positive phase III trial, met the primary endpoint and it will be submitted primarily to the European medical agencies very soon and we will see what happens. But I hope that we will have a new drug in our treatment armamentarium for stage three melanoma patients with fully resectable disease in the neoadjuvant intention.

Related Videos

Pancreatic Cancer

Belinda Lee, MBBS, on Early-Stage Pancreatic Cancer: New Data on Guiding Adjuvant Chemotherapy

Belinda Lee, MBBS, of Peter MacCallum Cancer Centre, Northern Health, Walter & Eliza Hall Institute, Melbourne, discusses findings from the AGITG DYNAMIC-Pancreas trial on the potential role of serial circulating tumor DNA testing after upfront surgery to guide adjuvant chemotherapy for early-stage disease (Abstract 107).

Gynecologic Cancers

Don S. Dizon, MD, on Ovarian and Other Extrarenal Clear Cell Carcinomas: Update on Nivolumab and Ipilimumab

Don S. Dizon, MD, of Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, discusses final phase II results of the BrUOG 354 trial showing that, for patients with ovarian and other extrarenal clear cell cancers, nivolumab and ipilimumab warrant further evaluation against standard treatment, given the historically chemotherapy-resistant nature of the disease (LBA5500).

Lymphoma

Yasmin H. Karimi, MD, on Large B-Cell Lymphoma: Follow-up on Subcutaneous Epcoritamab Monotherapy

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses 2.5-year follow-up data on epcoritamab monotherapy for patients with relapsed or refractory large B-cell lymphoma. The subcutaneous regimen continues to demonstrate durable responses (Abstract 7039).

Breast Cancer

Sherene Loi, MD, PhD, on Early-Stage Breast Cancer: Weighing the Prognostic Value of ctDNA Detection

Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre, discusses a circulating tumor DNA (ctDNA) analysis from a cohort of patients with early-stage breast cancer who were enrolled in the monarchE trial. This large cohort was studied to look at the usefulness of a personalized tumor-informed assay for ctDNA detection in early stage high-risk patients (LBA507).

Lymphoma

Joshua D. Brody, MD, on Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide

Joshua D. Brody, MD, of the Icahn School of Medicine at Mount Sinai, discusses results from the EPCORE NHL-2 study, which was designed to evaluate the safety and efficacy of epcoritamab-bysp plus rituximab and lenalidomide in the first-line setting for patients with follicular lymphoma and to assess epcoritamab as maintenance therapy in this population (Abstract 7014).

Advertisement

Advertisement




Advertisement